Melatonergic agonist regulates circadian clock genes and peripheral inflammatory and neuroplasticity markers in patients with depression and anxiety.

CONCLUSION: RMT treatment is able to restore phase-shifted melatonin markers, normalized the altered expression of the circadian genes, the levels of inflammatory cytokines and neurotrophins in patients with insomnia comorbid anxiety and depression.
PMID: 30851380 [PubMed - as supplied by publisher]

Source: Brain, Behavior, and Immunity - March 5, 2019 Category: Neurology Authors: Kumaran Satyanarayanan S, Chien YC, Pei-Chen Chang J, Huang SY, Guu TW, Su H, Su KP Tags: Brain Behav Immun Source Type: research